Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: Case reports

Catheterization and Cardiovascular Interventions

Volumn 52, Issue 4, 2001, Pages 468-472

  Manfredi, Joseph A ^a   Wall, Rivers P ^a   Sane, David C ^a   Braden, Gregory A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Heparin induced thrombocytopenia; Lepirudin

Indexed keywords

ANCROD; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DANAPAROID; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR;

AGED; ANTICOAGULATION; ARTERY CATHETERIZATION; ARTICLE; CARDIOVASCULAR DISEASE; CASE REPORT; DRUG SAFETY; HEPARINIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; POSTOPERATIVE COMPLICATION; THROMBOCYTOPENIA; THROMBOSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; HEPARIN; HIRUDIN THERAPY; HIRUDINS; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 0035066540     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.1102     Document Type: Article

References (26)

1. Heparin-induced thrombocytopenia and thrombosis: Clinical and laboratory studies
2. Heparin-associated thrombocytopenia
3. Heparin-induced thrombocytopenia: Pathogenesis, frequency, avoidance and management
4. Heparin-induced thrombocytopenia: A ten-year retrospective
5. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia
6. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay
7. A rapid and sensitive test for diagnosing heparin-induced thrombocytopenia
8. A diagnostic test for heparin-induced thrombocytopenia
9. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia
10. A sensitive and a specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia
11. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
12. Heparin-associated thrombocytopenia: The antibody is not heparin specific
13. Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia
14. Danaparoid (Orgaran) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: Effects on in vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG
15. Ancrod infusion for anticoagulation during and after PTCA in a patient with heparin-induced thrombocytopenia
16. Limitations of conventional treatment options for heparin-induced thrombocytopenia
17. Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome
18. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia: Heparin-Associated Thrombocytopenia Study (HAT) investigators
19. Recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia (HIT)
20. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
21. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin
22. Treatment with bivalirudin (Hirulog) as compared with heparin during angioplasty for unstable or postinfarction angina
23. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin
24. Hirudin: The promising antithrombotic
25. Novel antithrombotic drug in development
26. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial): Evaluation of c7E3 Fab in the prevention of ischemic complications trial